eligibility_summary
Eligible: DLBCL (incl. high-grade or transformed), ≥2 prior therapies, measurable disease, ECOG 0–1, adequate blood counts without transfusion/growth factors ≥7 days, negative and ongoing pregnancy testing if applicable. Exclude: active CNS/leptomeningeal involvement, solid-organ transplant, autoimmune/inflammatory disease needing systemic steroids/immunosuppressants within 1 yr, unresolved >Grade 1 toxicity, O2 dependence, active infection, stop antimicrobials ≥7 days pre-dose.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b, R/R B‑cell NHL. Interventions: JNJ‑80948543 plus JNJ‑75348780. Both are CD3 T‑cell engager bispecific antibody drugs (protein immunotherapies). Mechanism of action: each binds CD3 on T cells and a B‑cell tumor antigen (specific B‑cell targets not specified in the record) to redirect and activate cytotoxic T cells against malignant B cells, forming an immune synapse and inducing T‑cell–mediated killing. Targeted cells/pathways: CD3+ T cells (activation, proliferation, cytotoxic granule release) and B‑cell lymphoma cells expressing the respective antigens, leading to B‑cell depletion. Dosing: JNJ‑80948543 SC or IV (dose‑escalated to define RP2R) with fixed‑dose SC JNJ‑75348780, then dose expansion at RP2R.